GPCR biased ligands as novel heart failure therapeutics

Trends in Cardiovascular Medicine

Volumn 23, Issue 7, 2013, Pages 242-249

  Violin, Jonathan D ^a   Soergel, David G ^a   Boerrigter, Guido ^b   Burnett, John C ^b   Lark, Michael W ^a  

^a TREVENA INC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II [1 SARCOSINE 4 ISOLEUCINE 8 ISOLEUCINE]; ANGIOTENSIN II DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE; RELAXIN; TRV 120027; UNCLASSIFIED DRUG; VALSARTAN;

ACUTE HEART FAILURE; APOPTOSIS; BLOOD PRESSURE; CHEMOTAXIS; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; ENDOCYTOSIS; ENDOSOME; FLUID RETENTION; HEART FAILURE; HEART MUSCLE CELL; HEART OUTPUT; HEART PROTECTION; HUMAN; INOTROPISM; INTERNALIZATION; INTRACELLULAR SIGNALING; KIDNEY FUNCTION; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; REVIEW; SECOND MESSENGER;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG DISCOVERY; HEART FAILURE; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84883752677     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2013.01.002     Document Type: Review

References (64)

1. Ahn S., Kim J., Hara M.R., Ren X.R., Lefkowitz R.J. β-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. Journal of Biological Chemistry 2009, 284:8855-8865.
2. Aplin M., Christensen G.L., Schneider M., Heydorn A., Gammeltoft S., Kjolbye A.L., et al. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic & Clinical Pharmacology & Toxicology 2007, 100:289-295.
3. Aplin M., Christensen G.L., Schneider M., Heydorn A., Gammeltoft S., Kjolbye A.L., et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic & Clinical Pharmacology & Toxicology 2007, 100:296-301.
4. Awan N.A., Mason D.T. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. American Heart Journal 1996, 131:177-185.
5. Billet S., Bardin S., Verp S., Baudrie V., Michaud A., Conchon S., et al. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. Journal of Clinical Investigations 2007, 117:1914-1925.
6. Boerrigter G., Lark M.W., Whalen E.J., Soergel D.G., Violin J.D., Burnett J.C. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circulation Heart Failure 2011, 4:770-778.
7. Boerrigter G., Soergel D.G., Violin J.D., Lark M.W., Burnett J.C. TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circulation Heart Failure 2012.
8. Butler J., Forman D.E., Abraham W.T., Gottlieb S.S., Loh E., Massie B.M., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. American Heart Journal 2004, 147:331-338.
9. Chan D.P., Sandok E.K., Aarhus L.L., Heublein D.M., Burnett J.C. Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog. American Journal of Hypertension 1992, 5:354-360.
10. Chen H.H., Redfield M.M., Nordstrom L.J., Cataliotti A., Burnett J.C. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. American Journal of Physiology. Renal Physiology 2003, 284:F1115-1119.
11. Crozier I., Ikram H., Awan N., Cleland J., Stephen N., Dickstein K., et al. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995, 91:691-697.
12. De Lean A., Stadel J.M., Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. Journal of Biological Chemistry 1980, 255:7108-7117.
13. DeWire S.M., Ahn S., Lefkowitz R.J., Shenoy S.K. Beta-arrestins and cell signaling. Annual Review of Physiology 2007, 69:483-510.
14. DeWire S.M., Kim J., Whalen E.J., Ahn S., Chen M., Lefkowitz R.J. Beta-arrestin-mediated signaling regulates protein synthesis. Journal of Biological Chemistry 2008, 283:10611-10620.
15. DeWire S.M., Violin J.D. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circulation Research 2011, 109:205-216.
16. Dschietzig T., Alexiou K., Kinkel H.T., Baumann G., Matschke K., Stangl K. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling. Journal of Cardiac Failure 2011, 17:158-166.
17. Dschietzig T., Teichman S., Unemori E., et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. Journal of Cardiac Failure 2009, 15:182-190.
18. Du X.J., Bathgate R.A., Samuel C.S., Dart A.M., Summers R.J. Cardiovascular effects of relaxin: from basic science to clinical therapy. National Reviews Cardiology 2010, 7:48-58.
19. Fan G., Jiang Y.P., Lu Z., Martin D.W., Kelly D.J., Zuckerman J.M., et al. A transgenic mouse model of heart failure using inducible Galpha q. Journal of Biological Chemistry 2005, 280:40337-40346.
20. Felker G.M., O'Connor C.M., Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circulation Heart Failure 2009, 2:56-62.
21. Forman D.E., Butler J., Wang Y., Abraham W.T., O'Connor C.M., Gottlieb S.S., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. Journal of American College of Cardiology 2004, 43:61-67.
22. Gheorghiade M., Teerlink J.R., Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. American Journal of Cardiology 2005, 96:68G-73G.
23. Halls M.L., Cooper D.M. Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex. EMBO Journal 2010, 29:2772-2787.
24. Hollenberg N.K., Fisher N.D., Price D.A. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32:387-392.
25. Holloway A.C., Qian H., Pipolo L., Ziogas J., Miura S., Karnik S, et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Molecular Pharmacology 2002, 61:768-777.
26. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. Journal of American College of Cardiology 2009, 53:e1-e90.
27. Hunton D.L., Barnes W.G., Kim J., Ren X.R., Violin J.D., Reiter E., et al. Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Molecular Pharmacology 2005, 67:1229-1236.
28. Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Molecular Endocrinology 2006, 20:953-970.
29. Jafri S.M. The effects of beta blockers on morbidity and mortality in heart failure. Heart Failure Reviews 2004, 9:115-121.
30. Johnson W., Omland T., Hall C., Lucas C., Myking O.L., Collins C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. Journal of American College of Cardiology 2002, 39:1623-1629.
31. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship?. Molecular Pharmacology 2007, 72:1393-1401.
32. Kenakin T. New concepts in pharmacological efficacy at 7TM receptors. British Journal of Pharmacology 2012; 168(3): 554-75.
33. Kendall R.T., Strungs E.G., Rachidi S.M., Lee M.H., El-Shewy H.M., Luttrell D.K., et al. The beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1,Ile4,Ile8]angiotensin II regulates a robust G protein-independent signaling network. Journal of Biological Chemistry 2011, 286:19880-19891.
34. Kern A., Bryant-Greenwood G.D. Characterization of relaxin receptor (RXFP1) desensitization and internalization in primary human decidual cells and RXFP1-transfected HEK293 cells. Endocrinology 2009, 150:2419-2428.
35. Kim J., Ahn S., Rajagopal K., Lefkowitz R.J. Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. Journal of Biological Chemistry 2009, 284:11953-11962.
36. Kim K.S., Abraham D., Williams B., Violin J.D., Mao L., Rockman H.A. β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. American Journal of Physiology. Heart and Circulatory Physiology 2012, 303:H1001-1010.
37. McBride B.F., White C.M. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET. Journal of Clinical Pharmacology 2005, 45:6-24.
38. Noor N., Patel C.B., Rockman H.A. Beta-arrestin: a signaling molecule and potential therapeutic target for heart failure. Journal of Molecular and Cellular Cardiology 2011, 51:534-541.
39. Piedras-Renteria E.S., Sherwood O.D., Best P.M. Effects of relaxin on rat atrial myocytes. II. Increased calcium influx derived from action potential prolongation. American Journal of Physiology 1997, 272:H1798-1803.
40. Pitt B. Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?. American Journal of Hypertension 2002, 15:22S-27S.
41. Rademaker M.T., Charles C.J., Ellmers L.J., Lewis L.K., Nicholls M.G., Richards A.M. Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects. Hypertension 2011, 57:1136-1144.
42. Rajagopal K., Whalen E.J., Violin J.D., Stiber J.A., Rosenberg P.B., Premont R.T., et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:16284-16289.
43. Rakesh K., Yoo B., Kim I.M., Salazar N., Kim K.S., Rockman H.A. β-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Science Signaling 2010, 3:ra46.
44. Ruffolo R.R., Feuerstein G.Z., Ohlstein E.H. Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure. American Journal of Hypertension 1998, 11:9S-14S.
45. Samuel C.S., Du X.J., Bathgate R.A., Summers R.J. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacology & Therapeutics 2006, 112:529-552.
46. Shukla A.K., Xiao K., Lefkowitz R.J. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends in Biochemical Sciences 2011, 36:457-469.
47. Silvers S.M., Howell J.M., Kosowsky J.M., Rokos I.C., Jagoda A.S. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Annals of Emergency Medicine 2007, 49:627-669.
48. Solaro R.J., Kobayashi T. Protein phosphorylation and signal transduction in cardiac thin filaments. Journal of Biological Chemistry 2011, 286:9935-9940.
49. Swaminath G., Deupi X., Lee T.W., Zhu W., Thian F.S., Kobilka T.S., et al. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. Journal of Biological Chemistry 2005, 280:22165-22171.
50. Swaminath G., Xiang Y., Lee T.W., Steenhuis J., Parnot C., Kobilka B.K. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. Journal of Biological Chemistry 2004, 279:686-691.
51. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. New England Journal of Medicine 1992, 327:678-684.
52. Tamargo J., Amoros I., Barana A., Caballero R., Delpon E. New investigational drugs for the management of acute heart failure syndromes. Current Medicinal Chemistry 2010, 17:363-390.
53. Teerlink J.R. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. American Heart Journal 2003, 145:S26-33.
54. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. 2012. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet.
55. Teerlink J.R., Metra M., Felker G.M., Ponikowski P., Voors A.A., Weatherly B.D., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009, 373:1429-1439.
56. Teichman S.L., Unemori E., Dschietzig T., Conrad K., Voors A.A., Teerlink J.R., et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Failure Reviews 2009, 14:321-329.
57. Violin J.D., DeWire S.M., Yamashita D., Rominger D.H., Nguyen L., Schiller K., et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. Journal of Pharmacology and Experimental Therapeutics 2010, 335:572-579.
58. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends in Pharmacological Sciences 2007, 28:416-422.
59. Watson C., Chen G., Irving P., Way J., Chen W.J., Kenakin T. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Molecular Pharmacology 2000, 58:1230-1238.
60. Weber M.A. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. American Journal of Hypertension 1999, 12:189S-194S.
61. Wei H., Ahn S., Shenoy S.K., Karnik S.S., Hunyady L., Luttrell L., et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:10782-10787.
62. Wettschureck N., Rutten H., Zywietz A., Gehring D., Wilkie T.M., Chen J., et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nature Medicine 2001, 7:1236-1240.
63. Xiao K., Sun J., Kim J., Rajagopal S., Zhai B., Villen J., et al. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proceedings of the National Academy of Sciences of the United States of America 2010, 107:15299-15304.
64. Zhai P., Yamamoto M., Galeotti J., Liu J., Masurekar M., Thaisz J., et al. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. Journal of Clinical Investigations 2005, 115:3045-3056.